FACTORS AFFECTING TUMOR RESPONSE IN METASTATIC COLORECTAL CANCER PATIENTS TO FIRST AND SECOND LINE TREATMENT | ||
| ALEXMED ePosters | ||
| Article 1, Volume 7, Issue 1, January 2025, Pages 27-28 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2025.353588.2074 | ||
| Authors | ||
| Sherif Farouk ELZawawy1; Abdelsalam Attia Ismail2; Azza Darwish3; Jarred Ochieng Oduor* 4 | ||
| 1Department of Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria | ||
| 2Department Of Clinical Oncology and Nuclear Medicine , Faculty of Medicine , Alexandria University | ||
| 3Department of clinical oncology and nuclear medicine, Faculty of Medicine, Alexandria University | ||
| 4Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Egypt | ||
| Abstract | ||
| Metastatic colorectal cancer is the 3rd most prevalent cancer globally and ranks 2nd in terms of cancer-related deaths. In Egypt, colon and rectal cancers were the 9th and 18th most common malignancies and the 11th and 16th most prevalent cause of cancer-related mortality in the country, respectively. In the management of mCRC, there is need to determine predictive and prognostic factors that are likely to impact the tumor response and survival outcomes of systemic treatment. This is particularly true as the 1st and 2nd systemic lines of treatment are still the most effective treatment modalities available to control the illness. Real-world studies show that patients derive maximal benefit from 1st and 2nd line therapies as a later line of treatment do not provide a similar level of benefits. They must thus be optimized. AIM OF THE STUDY: The aim of this study was to identify the factors affecting tumor response in metastatic colorectal cancer patients to first line and second line treatment. PATIENTS AND METHODOLOGY: A retrospective cohort study investigating the factors affecting tumor response in mCRC patients to 1st and 2nd line treatment with a sample size of 110 patients managed for mCRC between January 2019 and December 2023. The study extracted information on demographic data, clinical, pathological, laboratory data, and molecular characteristics. The results were statistically analyzed with clinical outcomes. | ||
| Keywords | ||
| mCRC cancer; tumor response; PFS; OS | ||
|
Supplementary Files
|
||
|
Statistics Article View: 16 |
||
